{"": [64, 72, 0, 73, 1211, 0], "INTRODUCTION": [1212, 6277, 0], "Maximizing the Size and Diversity of Anti-SARS-CoV-2 Spike Nanobody Repertoire": [6302, 11917, 0], "High Affinity Nanobodies Across the Entire Spike Ectodomain that are Refractory to Common Spike Escape Mutants": [11918, 16022, 0], "The Nanobody Repertoire Has Favorable Stability Properties": [16023, 17721, 0], "Nanobodies Explore the Available Epitope Landscape of the Spike Ectodomain": [17722, 20849, 0], "Anti-RBD Nanobodies are Highly Effective Neutralizing Agents": [20850, 22091, 0], "Nanobody-based Neutralization Beyond the RBD": [22092, 23223, 0], "Oligomerization Strongly Enhances the Affinity and Neutralization Activity of Nanobodies": [23224, 24522, 0], "Nanobodies Neutralize SARS-CoV-1 and SARS-CoV-2 variants": [24523, 27576, 0], "Nanobodies Effectively Neutralize SARS-CoV-2 Infection in Human Primary Airway Epithelium": [27577, 30206, 0], "Synergistic Activity with Nanobody Combinations": [30207, 33245, 0], "Escape-Resistant Nanobody Cocktails": [33246, 38085, 0], "Insights into the Mechanism of Nanobody Binding and Neutralization": [38086, 47234, 0], "Perspectives": [47235, 48359, 0], "RESULTS AND DISCUSSION": [6278, 48359, 1], "Antigens": [48369, 49153, 0], "Immunization and Isolation of VHH Antibody Fractions": [49154, 50858, 0], "RT-PCR and DNA Sequencing": [50859, 52026, 0], "Identification of Nanobodies by Mass Spectrometry": [52027, 54907, 0], "Cloning and Purification of Nanobodies": [54908, 56041, 0], "Nanobody Screening": [56042, 57105, 0], "Surface Plasmon Resonance (SPR)": [57106, 58331, 0], "Differential Scanning Fluorimetry (DSF)": [58332, 58986, 0], "Lyophilization": [58987, 59284, 0], "Epitope Mapping": [59285, 61743, 0], "Mass Photometry": [61744, 62816, 0], "Cell Lines": [62817, 63474, 0], "Production of SARS-CoV-1, SARS-CoV-2, SARS-CoV-2 Variant Pseudotyped Lentiviral Reporter Particles": [63475, 64520, 0], "SARS-CoV-2 Pseudovirus Neutralization Assay": [64521, 65811, 0], "Nanobody Synergy": [65812, 66393, 0], "Structural Analysis": [66394, 69147, 0], "SARS-CoV-2 Stocks and Titers": [69148, 71394, 0], "Focus Forming Reduction Assay with Authentic SARS-CoV-2": [71395, 72999, 0], "SARS-CoV-2 Neutralization in Primary Airway Epithelial Cell (AEC) Cultures": [73000, 74264, 0], "rVSV/SARS-CoV-2 Neutralization Assays": [74265, 74944, 0], "Sequence Analyses": [74945, 75545, 0], "Selection of Virus Variants in the Presence of Nanobodies": [75546, 76922, 0], "Crosslinking Mass Spectrometry": [76923, 79033, 0], "METHODS": [48360, 79033, 1], "Supplementary Material": [79034, 83117, 0]}